ARTICLE | Clinical News
Rosuvastatin regulatory update
May 9, 2016 7:00 AM UTC
FDA granted final approval to an ANDA from Allergan for a generic version of cholesterol drug Crestor rosuvastatin. The company launched the generic HMG-CoA reductase inhibitor in the U.S. It is approved to treat patients with hypertriglyceridemia, primary dysbetalipoproteinemia and homozygous familial hypercholesterolemia (HoFH). ...